336 research outputs found

    Pathophysiology of plasma hypercoagulability in thrombosis

    Get PDF
    Blood coagulation abnormalities are the leading cause of death world-wide. Elevated procoagulant factor levels (hypercoagulability) have been correlated with increased thrombin generation and increased risk of arterial and venous thrombosis. This dissertation explores the role of hypercoagulability on various aspects of coagulation and thrombosis in vitro and in vivo. Thrombin generation tests are increasingly being employed as a high throughput, global measure of procoagulant activity. Thrombin generation was measured using calibrated automated thrombography (CAT) in platelet-free plasma (PFP) and platelet-rich plasma (PRP). The relative sensitivity of CAT parameters to elevated factors XI, IX, VIII, X, and prothrombin was: PFP initiated with 1 pM tissue factor (TF) > PFP initiated with 5 pM TF > PRP initiated with 1 pM TF. Monitoring the peak height following initiation with 1 pM TF in PFP was most likely to detect hypercoagulability (increased procoagulant factors). Epidemiologic studies have correlated elevated plasma fibrinogen (hyperfibrinogenemia) with risk of arterial and venous thrombosis. However, it is unknown whether hyperfibrinogenemia is a biomarker of disease or causative in the etiology. In mice, hyperfibrinogenemia significantly shortened the time to occlusion (TTO) after FeCl3 injury to the saphenous vein and carotid artery. Hyperfibrinogenemia increased thrombus fibrin content, promoted faster fibrin formation, and increased fibrin network density, strength, and stability and increased thrombus thrombolysis resistance in vivo. These data indicate hyperfibrinogenemia directly promotes thrombosis and thrombolysis resistance via enhanced fibrin formation and stability. Studies have correlated elevated plasma factor VIII (FVIII) with thrombosis. However, like hyperfibrinogenemia, it is unclear whether elevated FVIII is a biomarker or causative agent. In mice, elevated FVIII had no effect on 3-minute FeCl3 carotid artery injury, but shortened the TTO after 2-minute injury. Additionally, elevated FVIII increased circulating thrombin-antithrombin complexes and stabilized clots after 2- but not 3-minute FeCl3 injury. In vitro, elevated FVIII increased thrombin generation and accelerated platelet aggregation only when initiated by low TF. These results demonstrate dependence of FVIII thrombogenicity on extent of vascular injury. These findings provide a better understanding of how plasma hypercoagulability impacts thrombogenesis. Specifically, these data suggest causative yet differential roles for hyperfibrinogenemia and elevated FVIII in thrombosis

    Mid-Miocene cooling and the extinction of tundra in continental Antarctica

    Get PDF
    A major obstacle in understanding the evolution of Cenozoic climate has been the lack of well dated terrestrial evidence from high-latitude, glaciated regions. Here, we report the discovery of exceptionally well preserved fossils of lacustrine and terrestrial organisms from the McMurdo Dry Valleys sector of the Transantarctic Mountains for which we have established a precise radiometric chronology. The fossils, which include diatoms, palynomorphs, mosses, ostracodes, and insects, represent the last vestige of a tundra community that inhabited the mountains before stepped cooling that first brought a full polar climate to Antarctica. Paleoecological analyses, 40Ar/39Ar analyses of associated ash fall, and climate inferences from glaciological modeling together suggest that mean summer temperatures in the region cooled by at least 8°C between 14.07 ± 0.05 Ma and 13.85 ± 0.03 Ma. These results provide novel constraints for the timing and amplitude of middle-Miocene cooling in Antarctica and reveal the ecological legacy of this global climate transition

    Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma

    Get PDF
    Introduction—The bypassing agent recombinant factor VIIa (rFVIIa) is efficacious in treating bleeding in hemophilia patients with inhibitors. Efforts have focused on the rational engineering of rFVIIa variants with increased hemostatic potential. One rFVIIa analog (V158D/E296V/M298QFVIIa, NN1731) improves thrombin generation and clotting in purified systems, whole blood from hemophilic patients and factor VIII-deficient mice. Methods—We used calibrated automated thrombography and plasma clotting assays to compare effects of bypassing agents (rFVIIa, NN1731) on hemophilic clot formation, structure, and ability to resist fibrinolysis. Results—Both rFVIIa and NN1731 shortened the clotting onset and increased the maximum rate of fibrin formation and fibrin network density in hemophilic plasma clots. In the presence of tissue plasminogen activator, both rFVIIa and NN1731 shortened the time to peak turbidity (TTPeaktPA) and increased the area under the clot formation curve (AUCtPA). Phospholipids increased both rFVIIa and NN1731 activity in a lipid concentration-dependent manner. Estimated geometric mean concentrations of rFVIIa and NN1731 producing similar onset, rate, TTPeaktPA, and AUCtPA as seen with 100% factors VIII and IX were: 24.5, 74.3, 29.7, and 37.1 nM rFVIIa, and 8.6, 31.2, 9.0, and 11.3 nM NN1731, respectively. In each case, the NN1731 concentration was significantly lower than rFVIIa. Conclusions—These findings suggest that like rFVIIa, NN1731 improves the formation, structure, and stability of hemophilic clots. Higher lipid concentrations may facilitate assessment of both rFVIIa and NN1731 activity. NN1731 appears likely to support rapid clot formation in tissues with high endogenous fibrinolytic activity
    • …
    corecore